构建慢阻肺急性加重工具包:过去与现在的教训
综述回顾了慢阻肺急性加重(ECOPD)的诊断与治疗历史,指出尽管ECOPD与显著死亡、发病率及医疗费用相关,且再入院率高达四分之一,但诊疗工具自非侵入性通气引入25年来基本未变。文章认为需承认ECOPD异质性,仅凭临床表现无法识别病因或分层治疗。
要点
- ECOPD与显著死亡、发病率、生活质量下降及社会照护依赖增加相关。
- ECOPD常见且患病率上升,高达四分之一住院事件在30天内再入院。
- 诊疗工具基本未变,最后的新干预非侵入性通气已引入超过25年。
核心结论
- ECOPD诊疗进展缓慢,需承认并非所有急性加重都相同,临床表现 alone 无法识别病因或分层治疗。
研究设计与样本
- 综述,回顾ECOPD诊断与治疗的历史与现状。
主要发现
- ECOPD与显著死亡、发病率、生活质量下降及社会照护依赖增加相关。
- ECOPD常见且患病率上升,高达四分之一住院事件在30天内再入院。
- 诊疗工具基本未变,最后的新干预非侵入性通气已引入超过25年。
- ECOPD定义为呼吸症状急性加重导致额外治疗,基于症状和医疗效用,不描述病理,无法与其他急性呼吸困难原因区分。
- 对急性事件期间宿主免疫反应理解有限,床旁无可靠易得手段识别病因或指导治疗。
关键数值与推荐
- ECOPD定义为「呼吸症状急性加重导致额外治疗」。
- 皮质类固醇、短效支气管舒张剂联合或不联合抗生素已作为主要治疗超过30年。
临床怎么用
- 临床需认识到ECOPD异质性,不能仅凭临床表现识别病因或分层治疗。
- 目前床旁缺乏可靠易得手段识别病因或指导治疗。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the nineteenth century, it was recognised that acute attacks of chronic bronchitis were harmful. 140 years later, it is clearer than ever that exacerbations of chronic obstructive pulmonary disease (ECOPD) are important events. They are associated with significant mortality, morbidity, a reduced quality of life and an increasing reliance on social care. ECOPD are common and are increasing in prevalence. Exacerbations beget exacerbations, with up to a quarter of in-patient episodes ending with readmission to hospital within 30 days. The healthcare costs are immense. Yet despite this, the tools available to diagnose and treat ECOPD are essentially unchanged, with the last new intervention (non-invasive ventilation) introduced over 25 years ago.An ECOPD is 'an acute worsening of respiratory symptoms that results in additional therapy'. This symptom and healthcare utility-based definition does not describe pathology and is unable to differentiate from other causes of an acute deterioration in breathlessness with or without a cough and sputum. There is limited understanding of the host immune response during an acute event and no reliable and readily available means to identify aetiology or direct treatment at the point of care (POC). Corticosteroids, short acting bronchodilators with or without antibiotics have been the mainstay of treatment for over 30 years. This is in stark contrast to many other acute presentations of chronic illness, where specific biomarkers and mechanistic understanding has revolutionised care pathways. So why has progress been so slow in ECOPD? This review examines the history of diagnosing and treating ECOPD. It suggests that to move forward, there needs to be an acceptance that not all exacerbations are alike (just as not all COPD is alike) and that clinical presentation alone cannot identify aetiology or stratify treatment.
引用
- Sapey E, Bafadhel M, Bolton CE, et al. Building toolkits for COPD exacerbations: lessons from the past and present. Thorax. 2019. PMID: 31273049. doi:10.1136/thoraxjnl-2018-213035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。